271 related articles for article (PubMed ID: 21333645)
1. BAFF inhibition: a new class of drugs for the treatment of autoimmunity.
Liu Z; Davidson A
Exp Cell Res; 2011 May; 317(9):1270-7. PubMed ID: 21333645
[TBL] [Abstract][Full Text] [Related]
2. Targeting BAFF in autoimmunity.
Davidson A
Curr Opin Immunol; 2010 Dec; 22(6):732-9. PubMed ID: 20970975
[TBL] [Abstract][Full Text] [Related]
3. BAFF: a local and systemic target in autoimmune diseases.
Moisini I; Davidson A
Clin Exp Immunol; 2009 Nov; 158(2):155-63. PubMed ID: 19737141
[TBL] [Abstract][Full Text] [Related]
4. BAFF inhibition in SLE-Is tolerance restored?
Jackson SW; Davidson A
Immunol Rev; 2019 Nov; 292(1):102-119. PubMed ID: 31562657
[TBL] [Abstract][Full Text] [Related]
5. A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells.
Haselmayer P; Vigolo M; Nys J; Schneider P; Hess H
Eur J Immunol; 2017 Jun; 47(6):1075-1085. PubMed ID: 28383107
[TBL] [Abstract][Full Text] [Related]
6. B cell activating factor, its role in autoimmunity, and targeting in autoimmune diseases.
Krivosikova M; Dallos T; Maslinski W; Buc M
Bratisl Lek Listy; 2009; 110(3):137-45. PubMed ID: 19507632
[TBL] [Abstract][Full Text] [Related]
7. Development of autoimmune nephritis in genetically asplenic and splenectomized BAFF transgenic mice.
Fletcher CA; Groom JR; Woehl B; Leung H; Mackay C; Mackay F
J Autoimmun; 2011 Mar; 36(2):125-34. PubMed ID: 21216131
[TBL] [Abstract][Full Text] [Related]
8. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus.
Salazar-Camarena DC; Ortíz-Lazareno P; Marín-Rosales M; Cruz A; Muñoz-Valle F; Tapia-Llanos R; Orozco-Barocio G; Machado-Contreras R; Palafox-Sánchez CA
Cytokine; 2019 Feb; 114():115-127. PubMed ID: 30467093
[TBL] [Abstract][Full Text] [Related]
9. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.
Shi F; Xue R; Zhou X; Shen P; Wang S; Yang Y
Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):666-673. PubMed ID: 34519594
[TBL] [Abstract][Full Text] [Related]
10. BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorders.
Kalled SL; Ambrose C; Hsu YM
Expert Opin Ther Targets; 2003 Feb; 7(1):115-23. PubMed ID: 12556207
[TBL] [Abstract][Full Text] [Related]
11. BAFF, APRIL and human B cell disorders.
Tangye SG; Bryant VL; Cuss AK; Good KL
Semin Immunol; 2006 Oct; 18(5):305-17. PubMed ID: 16916610
[TBL] [Abstract][Full Text] [Related]
12. [BAFF: A regulatory cytokine of B lymphocytes involved in autoimmunity and lymphoid cancer].
Reyes S LI; León B F; Rozas V MF; González J P; Naves P R
Rev Med Chil; 2006 Sep; 134(9):1175-84. PubMed ID: 17171221
[TBL] [Abstract][Full Text] [Related]
13. BAFF-targeting therapy, a promising strategy for treating autoimmune diseases.
Sun J; Lin Z; Feng J; Li Y; Shen B
Eur J Pharmacol; 2008 Nov; 597(1-3):1-5. PubMed ID: 18793632
[TBL] [Abstract][Full Text] [Related]
14. Does the BAFF dysregulation play a major role in the pathogenesis of systemic lupus erythematosus?
Binard A; Le Pottier L; Saraux A; Devauchelle-Pensec V; Pers JO; Youinou P
J Autoimmun; 2008; 30(1-2):63-7. PubMed ID: 18155417
[TBL] [Abstract][Full Text] [Related]
15. TACI deletion protects against progressive murine lupus nephritis induced by BAFF overexpression.
Arkatkar T; Jacobs HM; Du SW; Li QZ; Hudkins KL; Alpers CE; Rawlings DJ; Jackson SW
Kidney Int; 2018 Oct; 94(4):728-740. PubMed ID: 29907458
[TBL] [Abstract][Full Text] [Related]
16. Myeloid cells, BAFF, and IFN-gamma establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice.
Scapini P; Hu Y; Chu CL; Migone TS; Defranco AL; Cassatella MA; Lowell CA
J Exp Med; 2010 Aug; 207(8):1757-73. PubMed ID: 20624892
[TBL] [Abstract][Full Text] [Related]
17. BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled?
Ramanujam M; Davidson A
Immunol Rev; 2008 Jun; 223():156-74. PubMed ID: 18613835
[TBL] [Abstract][Full Text] [Related]
18. An increase in B cell apoptosis by interfering BAFF-BAFF-R interaction with small synthetic molecules.
Moon EY; Yi KY; Lee S
Int Immunopharmacol; 2011 Oct; 11(10):1523-33. PubMed ID: 21620999
[TBL] [Abstract][Full Text] [Related]
19. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts.
Bossen C; Cachero TG; Tardivel A; Ingold K; Willen L; Dobles M; Scott ML; Maquelin A; Belnoue E; Siegrist CA; Chevrier S; Acha-Orbea H; Leung H; Mackay F; Tschopp J; Schneider P
Blood; 2008 Feb; 111(3):1004-12. PubMed ID: 17942754
[TBL] [Abstract][Full Text] [Related]
20. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease.
Rickert RC; Jellusova J; Miletic AV
Immunol Rev; 2011 Nov; 244(1):115-33. PubMed ID: 22017435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
